AOD-9604 and Autoimmune Disease: What Women Need to Know Before Starting

What Is AOD-9604 and Why Are Women Using It?

AOD-9604 is a 16-amino-acid synthetic peptide representing residues 176 to 191 of human growth hormone. It was originally developed by Metabolic Pharmaceuticals in Australia and studied through Phase II and Phase III trials for obesity, though it never received regulatory approval for any indication. Women are now encountering it through compounding pharmacies and telehealth peptide programs, primarily for body-composition goals.

The peptide's appeal is straightforward: it is marketed as triggering fat breakdown without the broad hormonal effects of full-length GH. Heffernan et al. (Endocrinology, 2001) demonstrated lipolytic activity in obese animal models and confirmed that this fragment does not activate the classical GH receptor, which is what causes most of the glucose-dysregulating and proliferative effects of exogenous GH. That paper is still the most-cited mechanistic anchor for AOD-9604 claims, and it involved no human autoimmune endpoints whatsoever.

Women specifically are drawn to AOD-9604 because of its overlap with conditions common in female patients: weight gain in perimenopause, visceral adiposity in PCOS, and metabolic slowdown postpartum. None of these use cases have been studied in controlled trials specific to women.

Why Autoimmune Disease Is a Distinct Concern for Women

Autoimmune diseases disproportionately affect women. Approximately 78% of people living with autoimmune diseases in the United States are women, a disparity driven by sex hormone effects on immune regulation, X-chromosome gene dosage, and microchimerism from pregnancy. Conditions like rheumatoid arthritis, lupus (SLE), Hashimoto's thyroiditis, multiple sclerosis, and Sjögren's syndrome skew heavily female.

This matters for AOD-9604 because growth hormone itself has well-characterized immunomodulatory effects. GH receptors are expressed on lymphocytes, macrophages, and natural killer cells. Growth hormone enhances T-cell development and augments pro-inflammatory cytokine signaling, which means any peptide that interacts with GH-related pathways, even partially, carries theoretical immune consequences that have not been ruled out.

AOD-9604 is designed to avoid GH-receptor activation. Whether it entirely succeeds in a complex human immune system, across hormonal states like perimenopause or active lupus flare, is not established.

The Evidence Gap: What the Research Actually Shows

The honest summary is that there are no published human trials of AOD-9604 in patients with autoimmune disease. Zero. This section maps what is known from adjacent evidence.

Animal and In Vitro Data

Heffernan et al. (2001) used obese mouse models to show that AOD-9604 reduces fat mass through lipolytic pathways that appear independent of GH-receptor binding. The study measured body weight, fat mass, and metabolic markers. Immune parameters were not measured. Extrapolating from this paper to autoimmune safety in a woman with lupus is a logical leap the data cannot support.

Separate cell-culture work on GH fragments has suggested that the C-terminal region of GH (which includes the 176-191 segment) may interact with heparan sulfate proteoglycans on cell surfaces. This receptor-independent binding could theoretically influence cell signaling in immune cells, but this has not been tested directly for AOD-9604 in any peer-reviewed publication on the allow-list sources.

Phase II and Phase III Human Trial Data (Non-Autoimmune Populations)

Metabolic Pharmaceuticals conducted clinical trials through the early 2000s in obese adults without autoimmune disease. A Phase IIb trial (METAOD005) reported no significant difference in weight loss versus placebo at doses of 1 mg, 5 mg, and 10 mg daily. Adverse event profiles from these trials did not flag autoimmune adverse events specifically, but the trials were short (12 weeks), excluded patients with immune-mediated conditions, and were not powered to detect rare immunological signals. Women were included in these trials but sex-stratified safety data have not been published in accessible primary literature.

What GH Biology Tells Us (With Caution About Extrapolation)

Because AOD-9604 derives from GH, its parent molecule's immune biology is worth understanding, with the explicit caveat that AOD-9604 may not behave identically. Full-length GH has bidirectional effects on autoimmunity: it can worsen inflammatory disease by upregulating Th1 cytokines, but it also supports thymic T-cell output, which is immunoprotective. GH receptors are present on peripheral blood mononuclear cells, and their activation modulates both innate and adaptive immune responses.

If AOD-9604 truly does not activate the GH receptor as Heffernan et al. suggest, then these GH-mediated immune effects may not apply. But "may not apply" is not the same as "confirmed safe."

The WomanRx editorial framework for evaluating unstudied peptides in autoimmune patients uses three tiers:

Tier 1 (Avoid): Active flare of systemic lupus erythematosus, active inflammatory arthritis, or any condition currently managed with immunosuppressants. The risk-to-benefit ratio is unfavorable when the benefit side of the equation has no human trial support.

Tier 2 (Proceed only with specialist co-management): Well-controlled autoimmune thyroid disease (Hashimoto's in stable hypothyroidism on levothyroxine), quiescent Sjögren's, or mild psoriasis not requiring biologics. Baseline inflammatory markers and thyroid function should be checked before starting and at 8 weeks.

Tier 3 (Lowest risk, still off-label): Women without a current autoimmune diagnosis but with a family history or elevated ANA. Monitoring is still warranted.

This framework is based on clinical reasoning, not trial data, and should not substitute for individual consultation with your rheumatologist or treating physician.

Sex-Specific Physiology: How Female Hormones Change the Picture

Estrogen, Immunity, and the GH Axis

Estrogen is a potent immunomodulator. Estradiol enhances B-cell activity and antibody production, which is one reason autoimmune diseases tend to flare during periods of hormonal change, including the perimenopause transition. Estrogen also regulates GH secretion: estrogen increases GH pulse amplitude and reduces IGF-1 negative feedback, meaning women already have a different GH axis set-point than men.

This has a practical consequence. A woman in perimenopause with falling estradiol levels, rising FSH, and disrupted GH pulsatility is not the same patient as the male subjects who made up a disproportionate share of peptide trial populations. How AOD-9604 interacts with a GH axis already dysregulated by menopause transition is genuinely unknown.

Reproductive Years and PCOS

Women with PCOS often have elevated GH pulse frequency alongside insulin resistance and chronic low-grade inflammation. Women with PCOS show elevated levels of inflammatory markers including CRP and IL-6 compared with BMI-matched controls. Introducing a peptide with GH-adjacent mechanisms into this inflammatory milieu carries theoretical risk of worsening the inflammatory phenotype, though no direct data exist.

For PCOS patients also managing autoimmune thyroid disease (Hashimoto's co-occurs with PCOS at rates higher than chance), the absence of AOD-9604 data in both conditions simultaneously is a real gap.

Perimenopause and Postmenopause

The perimenopausal immune shift is now well-documented. As estradiol declines, regulatory T-cell function diminishes and inflammatory cytokine tone rises. Women in early perimenopause show measurable increases in IL-1β and TNF-α compared with premenopausal baselines. A peptide with any immune-modulating potential, even theoretical, needs to be evaluated against this backdrop, and it has not been.

Postmenopausal women using AOD-9604 for visceral fat reduction are the demographic most likely to already carry autoimmune diagnoses. The lack of data is most consequential for this group.

Postpartum Thyroiditis: A Specific Risk to Name

Postpartum thyroiditis affects approximately 5 to 10% of women in the first year after delivery and is an autoimmune condition. It is often self-limiting, but some women transition to permanent hypothyroidism. A postpartum woman considering AOD-9604 for weight loss (a common driver) may be in an immunologically vulnerable window. Thyroid peroxidase antibodies should be checked before any peptide therapy is started in the postpartum period.

Pregnancy and Lactation Safety

AOD-9604 is contraindicated in pregnancy. No human pregnancy safety data exist. The peptide has not been assigned an FDA pregnancy category because it was never approved, but the absence of a category is not reassuring. The default position for any unapproved compound with no reproductive toxicology data in humans is avoidance.

Before starting AOD-9604: Women of reproductive age who are not using reliable contraception should not use this peptide. If you are actively trying to conceive, AOD-9604 should be stopped. No washout period has been established because no pharmacokinetic reproductive data exist in humans. A conservative clinical approach is to stop at least one full menstrual cycle before attempting conception.

During pregnancy: Stop immediately if pregnancy occurs. Inform your obstetric provider. No data support a specific monitoring protocol because there are no case reports or case series to draw conclusions from.

During lactation: No data exist on AOD-9604 transfer into human breast milk. The peptide is small (1,817 daltons), and small peptides can transfer into milk to varying degrees depending on lipophilicity and pH partitioning. Without transfer data, the precautionary recommendation is to avoid AOD-9604 while breastfeeding. The weight-loss rationale does not outweigh the unknown risk to a nursing infant.

Contraception requirement: Any woman on AOD-9604 who does not wish to become pregnant should use reliable contraception (hormonal, IUD, or barrier). This is not a teratogenicity warning based on known defects; it is a precautionary standard applied to all unapproved compounds with no reproductive safety data.

Who This May Be Right For, and Who Should Avoid It

Candidates Who May Warrant Lowest-Risk Discussion

• Postmenopausal women with no current autoimmune diagnosis, stable metabolic health, and a clear conversation with their provider about the evidence gaps
• Women with well-controlled hypothyroidism (Hashimoto's on stable levothyroxine dose) whose thyroid function has been normal for at least six months, and only with endocrinology input
• Women who have specifically discussed this with a rheumatologist or immunologist and received documented clearance

Women Who Should Avoid AOD-9604

• Any woman with active lupus, active inflammatory arthritis, active multiple sclerosis relapse, or any autoimmune condition currently requiring immunosuppressive therapy
• Pregnant women or women actively trying to conceive
• Breastfeeding women
• Women with a history of cancer (GH-axis peptides carry theoretical proliferative risk that has not been ruled out for AOD-9604)
• Women with uncontrolled thyroid disease, including newly diagnosed Hashimoto's where TPO antibody levels are high and thyroid function is still fluctuating
• Postpartum women within the first 12 months of delivery, given the risk of postpartum thyroiditis and general immune reconstitution occurring in that window

Regulatory Status and the 2024 FDA Compounding Update

The regulatory picture for AOD-9604 tightened significantly in 2024. The FDA placed AOD-9604 on its list of substances that present demonstrable difficulties for compounding, which effectively limits its availability through 503A compounding pharmacies. This category 2 designation does not mean the drug is banned, but it signals that the agency does not consider it appropriate for routine compounding based on available safety and efficacy data.

Women using AOD-9604 through telehealth platforms should be aware that the legal and supply field is actively shifting. If a compounding pharmacy is providing AOD-9604 without referencing this regulatory status, that is worth asking about directly.

Monitoring Recommendations for Women Who Proceed

If a woman with no active autoimmune disease, after a fully informed discussion with her prescriber and any relevant specialist, proceeds with AOD-9604, the following monitoring is clinically reasonable based on the peptide's GH-adjacent mechanism and known immune considerations:

Before Starting

• Complete metabolic panel (CMP) including fasting glucose and insulin
• Thyroid panel: TSH, free T4, TPO antibodies (especially postpartum or with family history of autoimmune thyroid disease)
• Inflammatory markers: CRP and ESR
• ANA screen if family history of lupus or Sjögren's
• Fasting lipid panel (lipolytic peptides can affect lipid profiles)
• Confirm negative pregnancy test

At 8 Weeks

• Repeat CMP, TSH, CRP
• Assess for new joint symptoms, rash, or fatigue that could indicate immune activation
• If ANA was positive at baseline, repeat ANA with titer and consider anti-dsDNA

At 16 Weeks or Discontinuation

• Repeat full panel if continuing
• Document any change in autoimmune disease activity if co-existing condition is present

No evidence-based monitoring protocol for AOD-9604 exists because no trial has generated this data. The above is expert-opinion-level guidance adapted from general principles of monitoring novel immunologically active compounds.

Drug Interactions Relevant to Women With Autoimmune Disease

Women with autoimmune conditions are often on multiple agents. The following interactions are theoretical (based on mechanism) rather than documented in AOD-9604-specific pharmacokinetic studies, because those studies do not exist in published literature.

Methotrexate: Used in rheumatoid arthritis, psoriatic arthritis, and lupus. No known pharmacokinetic interaction with AOD-9604, but both agents can affect folate metabolism and hepatic function. Liver enzyme monitoring is prudent.

Hydroxychloroquine: Used in lupus and Sjögren's. No documented interaction. Both agents affect metabolic pathways in ways that are poorly characterized in combination.

Levothyroxine: Thyroid hormone replacement is common in women with Hashimoto's. AOD-9604's lipolytic activity theoretically alters the distribution volume of lipophilic drugs. Whether this affects levothyroxine is unknown.

Biologic DMARDs (TNF inhibitors, IL-6 inhibitors): Women on biologics for rheumatoid arthritis, psoriatic arthritis, or Crohn's disease should consider this an absolute conversation to have with their rheumatologist before adding any peptide. The combined immune effects are entirely unstudied.

Oral contraceptives: OCP use affects IGF-1 and GH axis dynamics. Oral estrogens reduce IGF-1 levels through first-pass hepatic effects, which could theoretically modify how the GH axis responds to AOD-9604. The clinical significance is unknown.

Named Clinician Perspectives

The Endocrine Society's position on growth hormone and its analogues states that GH use for anti-aging or body composition in healthy adults lacks proven benefit and carries real risks, including potential effects on glucose metabolism and cell proliferation. While this guidance addresses full-length GH and not AOD-9604 specifically, the society's concern about GH-axis manipulation without sufficient evidence is directly relevant to a GH-derived fragment.

The American College of Rheumatology has published guidance noting that immunomodulatory supplements and unapproved compounds should be discussed with the treating rheumatologist before use in patients with systemic autoimmune diseases, given the potential for both disease flare and interaction with established therapies.

What the Evidence Gap Means in Practice

Women have been historically underrepresented in trials of novel metabolic compounds. The Phase II and III AOD-9604 trials that exist enrolled mixed-sex populations but have not published sex-stratified data on immune or endocrine outcomes in accessible primary literature. That means the question "Is AOD-9604 safe for a 47-year-old woman with quiescent Hashimoto's and perimenopausal weight gain?" cannot be answered from existing data. It is not a matter of finding the right study. The study does not exist.

This is not a reason to panic if you have already taken AOD-9604. Short-term use in the doses typically compounded (250 to 500 micrograms daily subcutaneously) is unlikely to trigger a dramatic immune event based on what is known about the peptide's mechanism. But "unlikely to trigger a dramatic event" is a very different statement from "demonstrated to be safe," and that distinction matters for women making informed decisions about their bodies.

Your prescriber should be able to explain specifically why AOD-9604 is being recommended for your individual case, what monitoring they plan to use, and what they will do if your inflammatory markers change. If those answers are vague, that is clinically meaningful information.